View Item 

Show simple item record

Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs
dc.contributor.authorBenjamin, William J.
dc.contributor.authorYalamanchi, Pratyusha
dc.contributor.authorTaylor, Jeremy M. G.
dc.contributor.authorLenze, Nicholas
dc.contributor.authorWorden, Francis P.
dc.contributor.authorChinn, Steven B.
dc.contributor.authorChen, Michelle M.
dc.date.accessioned2023-06-01T20:51:16Z
dc.date.available2024-07-01 16:51:14en
dc.date.available2023-06-01T20:51:16Z
dc.date.issued2023-06
dc.identifier.citationBenjamin, William J.; Yalamanchi, Pratyusha; Taylor, Jeremy M. G.; Lenze, Nicholas; Worden, Francis P.; Chinn, Steven B.; Chen, Michelle M. (2023). "Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs." Head & Neck 45(6): 1468-1475.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/176878
dc.description.abstractBackgroundThe impact of monoclonal antibody therapy (mAB) for advanced head and neck cancer on end-of-life health care utilization and costs has yet to be adequately studied.MethodsRetrospective cohort study of patients aged 65 and over with a diagnosis of head and neck cancer between 2007 and 2017 within the SEER-Medicare registry assessing the impact of mAB therapy (i.e., cetuximab, nivolumab, or pembrolizumab) on end-of-life health care utilization (ED visits, inpatient admissions, ICU admissions, and hospice claims) and costs.ResultsOf 12 544 patients with HNC, 270 (2.2%) utilized mAB therapy at the end-of-life period. On multivariable analyses adjusting for demographic and clinicopathologic characteristics, there was a significant association between mAB therapy and emergency department visits (OR: 1.38, 95% CI: 1.1–1.8, p = 0.01) and healthcare costs (β: $9760, 95% CI: 5062–14 458, p < 0.01).ConclusionsmAB use is associated with higher emergency department utilization and health care costs potentially due to infusion-related and drug toxicity expenses.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherhead and neck cancer
dc.subject.otherhealth care costs
dc.subject.otherhealth care utilization
dc.subject.otherend-of-life care
dc.titleImpact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176878/1/hed27359_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176878/2/hed27359.pdf
dc.identifier.doi10.1002/hed.27359
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceHeinonen T, Loimu V, Saarilahti K, Saarto T, Mäkitie A. End-of-life care pathway of head and neck cancer patients: single-institution experience. Eur Arch Otorhinolaryngol. 2018; 275 ( 2 ): 551. doi: 10.1007/s00405-017-4843-x
dc.identifier.citedreferenceZandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014; 50 ( 7 ): 627 - 632. doi: 10.1016/j.oraloncology.2014.04.003
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359 ( 11 ): 1116 - 1127. doi: 10.1056/nejmoa0802656
dc.identifier.citedreferenceBurtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394 ( 10212 ): 1915 - 1928. doi: 10.1016/S0140-6736(19)32591-7
dc.identifier.citedreferenceFerris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81: 45 - 51. doi: 10.1016/j.oraloncology.2018.04.008
dc.identifier.citedreferenceVukkadala N, Fardeen T, Ramchandran K, Divi V. End-of-life practice patterns in head and neck cancer. Laryngoscope. 2021; 131 ( 8 ): 1769 - 1773. doi: 10.1002/lary.29423
dc.identifier.citedreferenceMariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011; 103 ( 2 ): 117 - 128. doi: 10.1093/jnci/djq495
dc.identifier.citedreferenceGloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003; 8 ( 6 ): 541 - 552. doi: 10.1634/theoncologist.8-6-541
dc.identifier.citedreferenceNCI. Surveillance, Epidemiology and End Results (SEER) Program. https://seer.cancer.gov/
dc.identifier.citedreferenceNCI, CMS. SEER-Medicare Linked Database. https://healthcaredelivery.cancer.gov/seermedicare/
dc.identifier.citedreferenceBarosso G. How to identify hospital claims for emergency room visits in the medicare claims data. Research Data Assistance Center. https://resdac.org/articles/how-identify-hospital-claims-emergency-room-visits-medicare-claims-data
dc.identifier.citedreferenceVenkatesh AK, Mei H, Kocher EK, et al. Identification of emergency department visits in Medicare administrative claims: approaches and implications. Acad Emerg Med. 2017; 24 ( 4 ): 422 - 431. doi: 10.1111/acem.13140
dc.identifier.citedreferenceNCI. Comorbidity SAS Macro (2021 Edition). https://healthcaredelivery.cancer.gov/seermedicare/considerations/NCI.comorbidity.macro.sas
dc.identifier.citedreferenceKlabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17 ( 8 ): 584 - 590. doi: 10.1016/j.annepidem.2007.03.011
dc.identifier.citedreferenceFoley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010; 21 ( 7 ): 1455 - 1461. doi: 10.1093/annonc/mdp535
dc.identifier.citedreferenceMurphy CT, Galloway TJ, Handorf EA, et al. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer. 2015; 121 ( 8 ): 1204 - 1213. doi: 10.1002/cncr.29191
dc.identifier.citedreferenceGreenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016; 31 ( 4 ): 337 - 350. doi: 10.1007/s10654-016-0149-3
dc.identifier.citedreferenceChen MM, Rosenthal EL, Divi V. End-of-life costs and hospice utilization in patients with head and neck cancer. Otolaryngol Head Neck Surg. 2019; 161 ( 3 ): 439 - 441. doi: 10.1177/0194599819846072
dc.identifier.citedreferenceYeh J, Guddati AK. Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Cancer Res. 2020; 10 ( 6 ): 1821 - 1826.
dc.identifier.citedreferenceKeytruda: Cost Info and Financial Support. https://www.keytruda.com/financial-support/
dc.identifier.citedreferenceShuman AG, Yang Y, Taylor JMG, Prince ME. End-of-life care among head and neck cancer patients. Otolaryngol Head Neck Surg. 2011; 144 ( 5 ): 733 - 739. doi: 10.1177/0194599810397603
dc.identifier.citedreferenceHaun MW, Estel S, Rücker G, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017; 2017 ( 6 ): CD011129. doi: 10.1002/14651858.CD011129.pub2
dc.identifier.citedreferenceCampion FX, Larson LR, Kadlubek PJ, Earle CC, Neuss MN. Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes. J Oncol Pract. 2011; 7: 31s - 35s. doi: 10.1200/JOP.2011.000313
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed27359_am.pdf
Size:
346.0KB
Format:
PDF
View/Open
Name:
hed27359.pdf
Size:
650.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.